Illumina Q2 revenue rises 9.4% to $1.16B, but net income falls 11.9% to $207.0M

Filed July 31, 2026 · Period ending June 28, 2026 · Compared to 10-Q Aug 1, 2025 · ~1 min read

Key Changes

• high

  Revenue grew 9.4% to $1.16B, driven by NovaSeq X demand and the SomaLogic acquisition, but net income fell 11.9% to $207M.

  MD&A: Revenue verify on EDGAR →
• high

  Gross margin improved 60 bp to 66.2%, but underlying margin pressure persists from tariffs, product mix, and SomaLogic.

  MD&A: Gross Margin verify on EDGAR →
• high

  Operating income rose 14% to $245M, but higher legal, ERP, and compensation costs partially offset gains.

  MD&A: Operating Income verify on EDGAR →